LOGIN  |  REGISTER
Chimerix
Astria Therapeutics

CVS Health appoints Michael F. Mahoney to its Board of Directors

September 21, 2023 | Last Trade: US$44.36 0.58 1.32

WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE: BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.

"Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued focus on strengthening our engagement with consumers to improve their health and well-being."

Mahoney became the CEO of Boston Scientific Corporation in 2012 and became Chairman of the company's Board of Directors in 2016. With more than 45,000 global employees, Boston Scientific reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation, urology, and women's health.

"We're extremely pleased to have Mike join the Board," said Roger N. Farah, Independent Chair of the Board of CVS Health. "His knowledge and insight will be a tremendous asset, as will his background in leading the development of innovative solutions for patients."

Mahoney's career spans more than 25 years of success building market-leading medical device, capital equipment and health care IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson. Mahoney previously was President and CEO of Global Healthcare Exchange, a leading medical supply chain solutions company. For the first 12 years of his career, he advanced through a series of leadership roles at General Electric Medical Systems, including as General Manager of its Healthcare Information Technology business.

"CVS Health and Boston Scientific share many common goals, with a primary focus on making a real difference for the people and patients we serve," Mahoney said. "I hope that my experience within the health care industry will help me work with the Board and the management team to support and advance CVS Health's strategy."

Mahoney serves on the Board of the Boys & Girls Club of Boston and as the chair of the Board of Governors of the Boston College Chief Executives Club. He previously served on the Board of Directors of Baxter International Inc., a multinational health care company. He earned his B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

About CVS Health

CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

Media contact
Ethan Slavin
860-273-6095
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor contact
Larry McGrath
800-201-0938
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB